Optimal duration of trastuzumab for early HER2-positive...

Optimal duration of trastuzumab for early HER2-positive breast cancer

Specht, Jennifer M, Davidson, Nancy E
How much do you like this book?
What’s the quality of the file?
Download the book for quality assessment
What’s the quality of the downloaded files?
Volume:
389
Language:
english
Journal:
The Lancet
DOI:
10.1016/S0140-6736(17)30322-7
Date:
March, 2017
File:
PDF, 376 KB
english, 2017
Conversion to is in progress
Conversion to is failed